A Multi-Center, Open-Label, Phase Ib/II Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Sufatinib in Treating Advanced Neuroendocrine Tumors

Trial Profile

A Multi-Center, Open-Label, Phase Ib/II Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Sufatinib in Treating Advanced Neuroendocrine Tumors

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2017

At a glance

  • Drugs Sulfatinib (Primary)
  • Indications Neuroendocrine tumours
  • Focus Adverse reactions
  • Sponsors Hutchison MediPharma
  • Most Recent Events

    • 19 Jun 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.
    • 10 Mar 2017 Results published in the Chi-Med Media Release
    • 10 Mar 2017 According to a Chi-Med media release, results from this trial were presented at the 14th Annual Conference of European Neuroendocrine Tumor Society (ENETS)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top